Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor–Positive Tumors of Tamoxifen-Treated Breast Cancer Patients
暂无分享,去创建一个
John M.S. Bartlett | J. Bartlett | K. Nielsen | T. Kirkegaard | T. Cooke | L. Mcglynn | S. Tovey | Tove Kirkegaard | B. Dunne | Barbara Dunne | Timothy G. Cooke | Liane M. McGlynn | Fiona M. Campbell | Sven Müller | Sian M. Tovey | Kirsten V. Nielsen | S. Müller
[1] Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5 , 2003, Development.
[2] John M.S. Bartlett,et al. Can Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer? , 2005, Clinical Cancer Research.
[3] R. Lanz,et al. Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.
[4] J. Qin,et al. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. , 2004, Molecular cell.
[5] B. O’Malley,et al. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.
[6] Minetta C. Liu,et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling , 2003, Oncogene.
[7] P. Lønning,et al. Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.
[8] Rachel Schiff,et al. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. , 2003, Breast.
[9] R. Schiff,et al. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] P. Meltzer,et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.
[11] J. Bartlett,et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen , 2005, The Journal of pathology.
[12] Jiang Shou,et al. Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance , 2004, Clinical Cancer Research.
[13] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[14] Z. Hall. Cancer , 1906, The Hospital.
[15] J. Katzenellenbogen,et al. Coactivator proteins as determinants of estrogen receptor structure and function: spectroscopic evidence for a novel coactivator-stabilized receptor conformation. , 2005, Molecular endocrinology.
[16] D. Stern,et al. ErbBs in mammary development. , 2003, Experimental cell research.
[17] J. Font de Mora,et al. AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor , 2000, Molecular and Cellular Biology.
[18] P. Meltzer,et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] K. Grigor,et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer , 2003, British Journal of Cancer.
[20] D. Stern,et al. Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[21] B. O’Malley,et al. Rapid Estrogen-Induced Phosphorylation of the SRC-3 Coactivator Occurs in an Extranuclear Complex Containing Estrogen Receptor , 2005, Molecular and Cellular Biology.
[22] L. Murphy,et al. Altered expression of estrogen receptor coregulators during human breast tumorigenesis. , 2000, Cancer research.
[23] W. Gradishar. Tamoxifen--what next? , 2004, The oncologist.
[24] W. Gullick. c‐erbB‐4/HER4: friend or foe? , 2003, The Journal of pathology.
[25] B. Katzenellenbogen,et al. Modulation of estrogen receptor activity by selective coregulators , 2003, The Journal of Steroid Biochemistry and Molecular Biology.
[26] T. Kirkegaard,et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? , 2006, Histopathology.
[27] Baljit Singh,et al. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue , 2001, Breast Cancer Research and Treatment.
[28] T. Cooke,et al. A role for BRCA1 in sporadic breast cancer , 2003, British Journal of Cancer.
[29] S. Hilsenbeck,et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.
[30] R. Schiff,et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.
[31] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[32] K. Horwitz,et al. Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors , 1999, The Journal of Steroid Biochemistry and Molecular Biology.